Investors Buy High Volume of Progenics Pharmaceuticals Put Options (PGNX)
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) was the recipient of unusually large options trading on Thursday. Investors bought 5,158 put options on the company. This represents an increase of approximately 8,087% compared to the average volume of 63 put options.
PGNX has been the subject of several recent analyst reports. Zacks Investment Research cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. ValuEngine raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. BidaskClub raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 9th. Finally, Cantor Fitzgerald set a $15.00 target price on Progenics Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $12.35.
Shares of Progenics Pharmaceuticals (PGNX) opened at $6.69 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86. The stock has a market capitalization of $475.08, a price-to-earnings ratio of -8.47 and a beta of 3.12. Progenics Pharmaceuticals has a one year low of $4.60 and a one year high of $11.72.
WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/investors-buy-high-volume-of-progenics-pharmaceuticals-put-options-pgnx/1903386.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.